TYME is a New Jersey-based biotechnology company that develops and commercializes metabolism-based therapies for the treatment of solid tumors and hematologic cancers.
Business Model:
Revenue: $22M
Employees: 11-50
TYME was acquired by
Syros Pharmaceuticals.
The acquisition happend on 2022-07-07.
Details of the transaction were not public
Address: 1 Pluckemin Way
City: Bedminster
State: NJ
Zip: 07921
Country: US
TYME is a New Jersey-based biotechnology company that develops and commercializes metabolism-based therapies for the treatment of solid tumors and hematologic cancers.
Contact Phone:
+12124612315
Contact Email:
Listed Exchange:
NASDAQ
IPO Date:
3/13/2015
Ticker Symbol:
TYME
Opened: -/share
EBITDA | - |
Total Cash | - |
Total Debt | - |
Total Revenue | - |
Total Profit (Gross) | - |
PE Ratio | - |
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2020 | Post-IPO Equity | $20M | 3/2019 | Post-IPO Equity | $12M | 2/2018 | Post-IPO Equity | $23M | 3/2017 | Equity | $8.2M | 2/2021 | Post-IPO Equity | $100M |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|